Mangoceuticals, Inc. Stock

Equities

MGRX

US56270V1061

Healthcare Facilities & Services

Market Closed - Nasdaq 04:30:00 2024-06-04 pm EDT 5-day change 1st Jan Change
0.371 USD +6.00% Intraday chart for Mangoceuticals, Inc. -15.68% +33.98%
Sales 2022 0.01 Sales 2023 0.73 Capitalization 5.83M
Net income 2022 -2M Net income 2023 -9M EV / Sales 2022 * -
Net cash position 2022 330K Net cash position 2023 610K EV / Sales 2023 7,129,952 x
P/E ratio 2022 *
-
P/E ratio 2023
-0.48 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 60.62%
More Fundamentals * Assessed data
Dynamic Chart
Mangorx to Introduce ?Mojo? Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances CI
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care MT
Top Midday Gainers MT
Mangoceuticals, Inc. to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications CI
Mangoceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mangoceuticals Signs Securities Purchase Deal; Mexican Unit Enters Technical Deal With Emifarma MT
Mangoceuticals, Inc. announced that it expects to receive CAD 1.5 million in funding from Platinum Point Capital LLC CI
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024. CI
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024. CI
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024. CI
Top Premarket Gainers MT
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024. CI
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024. CI
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024. CI
More news
1 day+6.00%
1 week-15.68%
Current month-5.74%
1 month+40.53%
3 months+76.92%
6 months-46.00%
Current year+33.98%
More quotes
1 week
0.34
Extreme 0.34
0.44
1 month
0.21
Extreme 0.2128
1.12
Current year
0.14
Extreme 0.143
1.12
1 year
0.14
Extreme 0.143
2.38
3 years
0.14
Extreme 0.143
4.37
5 years
0.14
Extreme 0.143
4.37
10 years
0.14
Extreme 0.143
4.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 21-09-30
Director of Finance/CFO 60 22-09-30
Chief Operating Officer 38 22-09-30
Members of the board TitleAgeSince
Director/Board Member 49 22-10-13
Chief Executive Officer 45 21-09-30
Director/Board Member 44 22-10-13
More insiders
Date Price Change Volume
24-06-04 0.371 +6.00% 14,753,738
24-06-03 0.35 -11.08% 851,630
24-05-31 0.3936 -5.16% 545,763
24-05-30 0.415 -5.57% 469,713
24-05-29 0.4395 -0.11% 1,133,039

Delayed Quote Nasdaq, June 04, 2024 at 04:30 pm EDT

More quotes
Mangoceuticals, Inc. is primarily focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. The Company has developed and is commercially marketing a new brand of erectile dysfunction (ED) products under the brand name Mango and a brand of hair loss products under the brand name Grow. These products are produced at a compounding pharmacy using a proprietary combination of United States Food and Drug Administration (FDA) approved ingredients and are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. It is marketing and selling these branded ED and hair loss products exclusively online via its Website at www.MangoRx.com. Its customer platform connects consumers to licensed healthcare professionals through its Website for the provision of care via telehealth. It also owns a global patent portfolio of oral solution.
Calendar
More about the company